December 28, 2005

Discontinuing Prophylactic Transfusions Used to Prevent Stroke in Sickle Cell Disease

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Discontinuation of transfusion for the prevention of stroke in children with sickle cell disease results in a high rate of reversion to abnormal blood-flow velocities on Doppler studies and stroke. (ClinicalTrials.gov number, NCT00006182.)

Me gusta

Guardar

Cite This Study

Robert J. Adams (Wed,) studied this question.

synapsesocial.com/papers/69d975e7a1d151c65f68430a https://doi.org/https://doi.org/10.1056/nejmoa050460

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Efficacy of transfusion therapy for one to two years in patients with sickle cell disease and cerebrovascular accidents1980 · 160 citations
2The randomization and stratification of patients to clinical trials1974 · 614 citations
3Lactic Acid Dehydrogenase Activity and Plasma Hemoglobin Elevations in Sickle Cell Disease1969 · 46 citations
4Middle cerebral artery blood velocity and cerebral blood flow in sickle cell disease.1991 · 40 citations
5Discrete sequential boundaries for clinical trials1983 · 1,740 citations

Me gusta

Guardar